Teachers Retirement System of The State of Kentucky Has $1.65 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Teachers Retirement System of The State of Kentucky lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.9% during the 3rd quarter, Holdings Channel reports. The firm owned 15,318 shares of the medical equipment provider’s stock after selling 1,305 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Zimmer Biomet were worth $1,653,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZBH. BLB&B Advisors LLC boosted its stake in Zimmer Biomet by 2.1% in the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 100 shares during the last quarter. FWG Holdings LLC boosted its position in shares of Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares during the last quarter. Financial Advocates Investment Management grew its stake in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the period. M&R Capital Management Inc. increased its holdings in Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 105 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC lifted its stake in Zimmer Biomet by 5.1% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 106 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH opened at $108.08 on Wednesday. The business’s 50-day simple moving average is $107.90 and its 200 day simple moving average is $108.55. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm has a market capitalization of $21.52 billion, a PE ratio of 20.55, a PEG ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.65 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZBH has been the subject of a number of recent analyst reports. Oppenheimer lowered their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Raymond James cut their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. BTIG Research decreased their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. TD Cowen dropped their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Finally, Barclays lowered their price target on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $123.28.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.